Moxifloxacin-and rifapentine-based regimens are under investigation for the treatment of tuberculosis. However, rifapentine may induce enzymes that metabolize moxifloxacin, resulting in decreased moxifloxacin concentrations. In this phase I, two-period, sequential-design study, 13 subjects received 400 mg moxifloxacin daily for 4 days followed by daily moxifloxacin coadministered with 900 mg rifapentine thrice weekly. Pharmacokinetic analyses were performed after the 4th and 19th doses of moxifloxacin and after the 1st and 7th doses of rifapentine. For moxifloxacin, the mean area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) decreased by 17.2% (P ؍ 0.0006) when the drug was coadministered with rifapentine, and the mean half-life (t 1/2 ) decreased from 11.1 to 8.9 h (P ؍ 0.0033). For rifapentine, the mean AUC 0-48 after seven thrice-weekly doses decreased by 20.3% (P ؍ 0.0035) compared to the AUC 0-48 after the first dose, and the mean t 1/2 decreased from 18.5 to 14.8 h (P ؍ 0.0004). The AUC 0-48 for the 25-desacetyl-rifapentine metabolite diminished 21%. Two days after completing the study drugs, one subject developed a fever and hepatitis, and another developed a flu-like illness with a rash. In conclusion, rifapentine modestly reduced moxifloxacin concentrations. Changes consistent with rifapentine autoinduction of metabolism were seen. Adverse reactions in two subjects may have represented rifamycin hypersensitivity syndrome, although some features were atypical.Tuberculosis (TB) is a leading cause of infectious disease death worldwide (7). Novel treatment strategies are needed to shorten the duration of treatment required for cure (currently 6 months), improve cure rates, and prevent the emergence of drug resistance.Moxifloxacin (MXF) and the long-lived rifamycin derivative rifapentine (RPT) are being studied for TB treatment. RPT is approved for use in combination TB treatment, but a dose of 600 mg (ϳ10 mg/kg of body weight) once weekly during the continuation phase of treatment has been associated with unacceptably high relapse rates in some populations (3, 31; Hoechst Marion Roussel, FDA new-drug application 21-024). In a mouse model of TB treatment, RPT administered thrice weekly at 15 mg/kg/dose in combination with MXF decreases to 3 months the duration of treatment required for cure (20,21,23,25). The optimal dose of RPT for the treatment of TB in humans has not been determined.Several pharmacologic issues regarding the concomitant use of RPT and MXF merit investigation. First, MXF is metabolized by sulfation and glucuronidation (Avelox package insert), and RPT may induce the enzymes responsible for these biotransformations (5). Coadministration of MXF with rifampin, a more potent inducer than RPT, results in reduced MXF concentrations (19,32). In addition, RPT may induce its own metabolism, decreasing its plasma concentrations and those of its active metabolite, 25-desacetyl-RPT (14, 23). Finally, the tolerability of 900 mg of RPT administered thrice weekly in combination wit...